1. Home
  2. PRAX
  3. PRAX News

Latest Praxis Precision Medicines Inc. (PRAX) News on June 1, 2025

Ulta Stock Jumps as Beauty Product Spending Continues
PRAX

Investopedia

2 days ago

Ulta Stock Jumps as Beauty Product Spending Continues

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy
PRAX

GlobeNewswire

2 days ago

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
PRAX

GlobeNewswire

2 days ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Northrop Grumman Raises $1 Billion Via Debt
PRAX

Benzinga

2 days ago

Northrop Grumman Raises $1 Billion Via Debt

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy
PRAX

GlobeNewswire

2 days ago

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

PRAX

Newsfile

2 days ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast
PRAX

GlobeNewswire

2 days ago

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

The York Water Company Files a Rate Request Based on $145 Million in Investment
PRAX

GlobeNewswire

2 days ago

The York Water Company Files a Rate Request Based on $145 Million in Investment

Praxis Precision Medicines to Participate in Upcoming Conferences
PRAX

GlobeNewswire

12 days ago

Praxis Precision Medicines to Participate in Upcoming Conferences

PRAX

MT Newswires

25 days ago

Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target

PRAX

MT Newswires

a month ago

Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
PRAX

GlobeNewswire

a month ago

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)
PRAX

Simply Wall St.

a month ago

Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

a month ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
PRAX

GlobeNewswire

a month ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
PRAX

GlobeNewswire

2 months ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Praxis Precision Medicines to Participate in Upcoming April Conferences
PRAX

GlobeNewswire

2 months ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

2 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
PRAX

Simply Wall St.

2 months ago

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
PRAX

GlobeNewswire

2 months ago

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

3 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision price target lowered to $85 from $150 at Needham
PRAX

TipRanks

3 months ago

Praxis Precision price target lowered to $85 from $150 at Needham

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
PRAX

GlobeNewswire

3 months ago

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

PRAX

MT Newswires

3 months ago

Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating

PRAX

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

PRAX

MT Newswires

3 months ago

Wedbush Downgrades Praxis Precision Medicines to Underperform From Neutral, Cuts Price Target to $26 From $57; Shares Fall

PRAX

MT Newswires

3 months ago

Top Midday Decliners

PRAX

MT Newswires

3 months ago

Sector Update: Health Care Stocks Softer Friday Afternoon

PRAX

MT Newswires

3 months ago

Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
PRAX

Zacks

3 months ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

PRAX

MT Newswires

3 months ago

Praxis Precision Medicines Says it Gets Recommendation From IDMC to Stop Study 1 of Essential3 Program

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
PRAX

GlobeNewswire

3 months ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PRAX

Zacks

3 months ago

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PRAX

Zacks

3 months ago

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

PRAX

MT Newswires

4 months ago

Deutsche Bank Initiates Coverage on Praxis Precision Medicines With Buy Rating, $111 Price Target

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

4 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Present at Two February Investor Conferences
PRAX

GlobeNewswire

4 months ago

Praxis Precision Medicines to Present at Two February Investor Conferences

PRAX

MT Newswires

4 months ago

Truist Securities Adjusts Price Target on Praxis Precision Medicines to $175 From $150, Keeps Buy Rating

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
PRAX

GlobeNewswire

5 months ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
PRAX

GlobeNewswire

5 months ago

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

PRAX

MT Newswires

5 months ago

Praxis Precision Medicines Files for Mixed Shelf, $250 Million Common Stock Sale

PRAX

MT Newswires

5 months ago

Praxis Says FDA Grants Rare Pediatric Disease Designation to Relutrigine to Treat Dravet Syndrome

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
PRAX

GlobeNewswire

5 months ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Praxis Precision Medicines to Present at Upcoming December Investor Conferences
PRAX

GlobeNewswire

6 months ago

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
PRAX

GlobeNewswire

6 months ago

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
PRAX

Simply Wall St.

7 months ago

Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...
PRAX

GuruFocus.com

7 months ago

Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
PRAX

GlobeNewswire

7 months ago

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

PRAX

MT Newswires

7 months ago

Wedbush Raises Praxis Precision Medicines Price Target to $57 From $51, Maintains Neutral Rating

PRAX

MT Newswires

7 months ago

Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
PRAX

Zacks

7 months ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
PRAX

GlobeNewswire

7 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
PRAX

GlobeNewswire

7 months ago

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
PRAX

Simply Wall St.

7 months ago

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Health Care Roundup: Market Talk
PRAX

The Wall Street Journal

8 months ago

Health Care Roundup: Market Talk

Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals
PRAX

Insider Monkey

8 months ago

Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
PRAX

Zacks

8 months ago

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
PRAX

GlobeNewswire

8 months ago

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

PRAX

GuruFocus.com

8 months ago

Perceptive Advisors LLC Adjusts Stake in Praxis Precision Medicines Inc

Praxis Precision Medicines to Participate in Upcoming Investor Conferences
PRAX

GlobeNewswire

9 months ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
PRAX

Zacks

9 months ago

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
PRAX

GlobeNewswire

9 months ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

PRAX

MT Newswires

9 months ago

Wedbush Adjusts Price Target on Praxis Precision Medicines to $51 From $48, Maintains Neutral Rating

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
PRAX

Benzinga

9 months ago

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
PRAX

GlobeNewswire

9 months ago

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
PRAX

GlobeNewswire

9 months ago

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
PRAX

Zacks

10 months ago

Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
PRAX

Zacks

10 months ago

Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
PRAX

GlobeNewswire

10 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
PRAX

Zacks

10 months ago

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

PRAX

MT Newswires

10 months ago

Oppenheimer Starts Praxis Precision Medicines With Outperform Rating, $134 Price Target

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
PRAX

Zacks

10 months ago

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

PRAX

MT Newswires

a year ago

Needham Initiates Praxis Precision Medicines at Buy With $145 Price Target

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
PRAX

Zacks

a year ago

Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?

Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure
PRAX

Investor's Business Daily

a year ago

Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate
PRAX

Simply Wall St.

a year ago

This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate

Praxis Precision Medicines to Participate in Upcoming Investor Conferences
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
PRAX

Simply Wall St.

a year ago

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
PRAX

Zacks

a year ago

Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?

PRAX

MT Newswires

a year ago

Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
PRAX

Zacks

a year ago

Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why

Praxis Precision Medicines to Participate in Upcoming April Conferences
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Health Care Roundup: Market Talk
PRAX

The Wall Street Journal

a year ago

Health Care Roundup: Market Talk

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
PRAX

Zacks

a year ago

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Praxis Precision Medicines, Inc. Announces Proposed Public Offering
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis (PRAX) Surges on Positive Epilepsy Study Results
PRAX

Zacks

a year ago

Praxis (PRAX) Surges on Positive Epilepsy Study Results

Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High
PRAX

Investor's Business Daily

a year ago

Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High

Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big
PRAX

Investor's Business Daily

a year ago

Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Praxis Precision Medicines to Host PRAX-628 Program Update
PRAX

GlobeNewswire

a year ago

Praxis Precision Medicines to Host PRAX-628 Program Update

A Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
PRAX

Simply Wall St.

a year ago

A Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
PRAX

Zacks

a year ago

What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?

Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates
PRAX

GuruFocus.com

a year ago

Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates

Share on Social Networks: